A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
about
Dehydroepiandrosterone for systemic lupus erythematosusCurrent and emerging treatment options in the management of lupusHydroxychloroquine-related retinal toxicityTreatment of Bullous Systemic Lupus ErythematosusPediatric lupus nephritis: Management updateBaseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).Women, kidney disease, and pregnancyHydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.Interferon-alpha: a therapeutic target in systemic lupus erythematosusA conceptual framework for clinical trials in SLE and other multisystem diseases.Methodological issues of corticosteroid use in SLE clinical trials.Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United StatesEndpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.Therapy of systemic lupus erythematosus: new agents and new evidence.Antimalarial therapy: a panacea for mild lupus?Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations.Antimalarials--the 'real' advance in lupus.Pregnancy and lupus nephritis.Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.Toll-like receptors as potential therapeutic targets for multiple diseases.Treatment of cutaneous lupus erythematosus.Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.Systemic lupus erythematosus. How to manage, when to refer.Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma.Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.Thrombosis in systemic lupus erythematosus: a review articleDisease activity assessment in SLE: do we have the right instruments?Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosusJoint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
P2860
Q24243533-F3796746-8DA2-431D-9E3F-5B8041F7C119Q26741266-683FCA37-B330-4D45-914D-C27C8D0CF31EQ26782822-3F9B9D61-C4CA-4698-B7A4-D49C8E41B355Q28087628-C6821F0F-70EB-413A-8CCB-50F5E182A758Q28660110-09D2BBB0-0519-451A-BDE4-8F05882D6347Q30645037-B2865CCE-EE74-4498-BDAC-B6DF0BB5C746Q31107094-8FD32B00-4238-481F-9923-61D9D1255D78Q31129756-EB037D59-A351-455D-AA3B-3519F6E323F6Q33410001-02F97623-951D-4FEE-BDC7-C46A04134D66Q33411608-B1D5EE6B-4187-4660-9A87-35BF13E07C72Q33422958-814E2C13-2881-41E7-BC05-10DA062BC21AQ33455990-0CB3A845-FC0A-4C5B-A23D-58DC4BD5B663Q33529416-EC2EFDA6-4C4E-4E3D-B1A6-D0A4D4C82816Q33555419-59E5E003-58F0-410C-AC78-EEACAF0731A3Q33731760-683924BC-1431-4129-9271-F71C713AA69DQ33744320-5386F50B-95C6-4C44-8D4A-5FDC4FC882C8Q33777430-3484D238-0B9C-4ABF-81CA-171A8C31CB69Q33777440-06A6B41C-0EAC-4588-986D-0CE33C82956AQ33913777-AB6E7EAA-989A-4538-9F3D-ABFCEE0F27EEQ33945242-941B66C7-49CD-46DA-869A-E6C2CE305284Q33957431-65C42AE1-3AA9-4845-AEB1-FC03191D9185Q34074960-17DC0F8D-7D64-4765-967B-1684F703C13DQ34226976-EE1B6A3B-DBC9-443B-816E-20B0E9C04200Q34227000-7D30B6B8-C038-4241-BD76-CEC7214EACE0Q34297582-0E623174-C0E0-4600-8F87-F4C5854E5BF5Q34417671-739934B7-359D-41E7-833C-ABF3776F0767Q34604474-ACD32801-8C93-4F0F-AB5A-3330CB4CDAC2Q34932177-4FBDB03C-AAC2-4A93-89A4-2877B14C19BEQ35222834-7C21C9CA-276D-4661-ABA8-D6F68F28EB30Q35456519-1C5B831E-326C-4B60-A742-CBF75A92BCB4Q35597979-D6697577-41C2-41C6-86BF-880658E5679CQ35686749-196C19E8-2AB2-4C1F-ABAB-157E2B15335DQ35824537-3C6165D1-B33C-46A7-899D-58AD9388F2E6Q35877606-6BB6327D-46EE-4935-8EB1-80BF6154C018Q36074980-1FDC9992-9E04-476C-BFD5-C2E5FC3F3F0BQ36147794-8B59791E-19C6-4D5C-B64D-C1DE6682F4D2Q36171764-55CFD82F-D6C6-42D2-8E8D-4A14C2BA1A49Q36240425-CEA0FD5C-45F0-46FA-B11A-0A8CE31CAE2CQ36246166-6164F2B1-FEE8-4DA4-BFEA-8071274AF974Q36302245-36644CD5-DC46-4A4A-A53D-7F2FFAF97733
P2860
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
A randomized study of the effe ...... systemic lupus erythematosus.
@en
type
label
A randomized study of the effe ...... systemic lupus erythematosus.
@en
prefLabel
A randomized study of the effe ...... systemic lupus erythematosus.
@en
P1476
A randomized study of the effe ...... systemic lupus erythematosus.
@en
P2093
Canadian Hydroxychloroquine Study Group
P304
P356
10.1056/NEJM199101173240303
P407
P577
1991-01-01T00:00:00Z